The critique discusses fifty eight peptides in different clinical phases, indicating a sturdy pipeline of peptide therapies focusing on PPIs. These strategies open up new avenues for therapies tailor-made to combat specific breast cancer subtypes and glioblastoma by honing in on integrins, fibronectins, and matrix metalloproteinases. Peptide drug development entered https://alicej319ihn4.bloggactivo.com/profile